• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

藤黄酸及其衍生物作为抗肿瘤药物的研究进展。

Research Progress in the Field of Gambogic Acid and Its Derivatives as Antineoplastic Drugs.

机构信息

Heilongjiang University of Chinese Medicine, Harbin 150040, China.

Key Laboratory of Chinese Materia Medica (Ministry of Education), Heilongjiang University of Chinese Medicine, Harbin 150040, China.

出版信息

Molecules. 2022 May 4;27(9):2937. doi: 10.3390/molecules27092937.

DOI:10.3390/molecules27092937
PMID:35566290
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9102264/
Abstract

Gambogic acid (GA) is a natural product with a wide range of pharmacological properties. It plays an important role in inhibiting tumor growth. A large number of GA derivatives have been designed and prepared to improve its shortcomings, such as poor water solubility, low bioavailability, poor stability, and adverse drug effects. So far, GA has been utilized to develop a variety of active derivatives with improved water solubility and bioavailability through structural modification. This article summarized the progress in pharmaceutical chemistry of GA derivatives to provide a reference and basis for further study on structural modifications of GA and expansion of its clinical applications.

摘要

藤黄酸(GA)是一种具有广泛药理活性的天然产物。它在抑制肿瘤生长方面发挥着重要作用。为了改善 GA 的缺点,如较差的水溶性、低生物利用度、较差的稳定性和不良的药物效应,已经设计和制备了大量的 GA 衍生物。到目前为止,已经通过结构修饰将 GA 用于开发各种具有改善的水溶性和生物利用度的活性衍生物。本文总结了 GA 衍生物的药物化学进展,为进一步研究 GA 的结构修饰和扩大其临床应用提供了参考和依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac0/9102264/4a26e576ebf5/molecules-27-02937-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac0/9102264/70757e809345/molecules-27-02937-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac0/9102264/813c586ddf58/molecules-27-02937-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac0/9102264/c5b6eb762d34/molecules-27-02937-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac0/9102264/6d8c18bcdd3d/molecules-27-02937-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac0/9102264/d2f39bbf09e4/molecules-27-02937-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac0/9102264/03703e4d29fc/molecules-27-02937-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac0/9102264/35b8920a39df/molecules-27-02937-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac0/9102264/63158752975b/molecules-27-02937-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac0/9102264/ed6ac1b2986e/molecules-27-02937-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac0/9102264/4a26e576ebf5/molecules-27-02937-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac0/9102264/70757e809345/molecules-27-02937-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac0/9102264/813c586ddf58/molecules-27-02937-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac0/9102264/c5b6eb762d34/molecules-27-02937-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac0/9102264/6d8c18bcdd3d/molecules-27-02937-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac0/9102264/d2f39bbf09e4/molecules-27-02937-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac0/9102264/03703e4d29fc/molecules-27-02937-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac0/9102264/35b8920a39df/molecules-27-02937-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac0/9102264/63158752975b/molecules-27-02937-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac0/9102264/ed6ac1b2986e/molecules-27-02937-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac0/9102264/4a26e576ebf5/molecules-27-02937-g010.jpg

相似文献

1
Research Progress in the Field of Gambogic Acid and Its Derivatives as Antineoplastic Drugs.藤黄酸及其衍生物作为抗肿瘤药物的研究进展。
Molecules. 2022 May 4;27(9):2937. doi: 10.3390/molecules27092937.
2
[Progress in research of the structural optimization of natural product-like Garcinia caged xanthones].[天然产物样藤黄属笼状呫吨酮结构优化的研究进展]
Yao Xue Xue Bao. 2014 Mar;49(3):293-302.
3
Studies on chemical modification and biology of a natural product, gambogic acid (II): Synthesis and bioevaluation of gambogellic acid and its derivatives from gambogic acid as antitumor agents.天然产物藤黄酸的化学修饰与生物学研究(II):藤黄酸及其衍生物的合成与生物评价作为抗肿瘤剂。
Eur J Med Chem. 2010 Sep;45(9):4343-53. doi: 10.1016/j.ejmech.2010.04.037. Epub 2010 May 13.
4
Design, Synthesis and Anti-cancer Evaluation of Nitrogen-containing Derivatives of 30-Carboxyl of Gambogic Acid.设计、合成并评价 30-羧基藤黄酸的含氮衍生物的抗癌活性。
Anticancer Agents Med Chem. 2024;24(6):454-463. doi: 10.2174/0118715206279725231208065031.
5
Novel natural-product-like caged xanthones with improved druglike properties and in vivo antitumor potency.具有改善的类药物性质和体内抗肿瘤效力的新型天然产物样笼状呫吨酮。
Bioorg Med Chem Lett. 2015 Jun 15;25(12):2584-8. doi: 10.1016/j.bmcl.2015.04.031. Epub 2015 Apr 18.
6
'Click Chemistry' Synthesis of Novel Natural Product-Like Caged Xanthones Bearing a 1,2,3-Triazole Moiety with Improved Druglike Properties as Orally Active Antitumor Agents.新型天然产物类似笼状黄烷酮的“点击化学”合成,具有改善的类药性,作为口服活性抗肿瘤药物,含有 1,2,3-三唑部分。
Molecules. 2017 Oct 27;22(11):1834. doi: 10.3390/molecules22111834.
7
Improving aqueous solubility and antitumor effects by nanosized gambogic acid-mPEG₂₀₀₀ micelles.纳米藤黄酸-mPEG₂₀₀₀ 胶束提高水溶解度和抗肿瘤作用。
Int J Nanomedicine. 2014;9:243-55. doi: 10.2147/IJN.S54050. Epub 2013 Dec 27.
8
Studies on chemical-structure modification and structure-activity relationship of gambogic acid derivatives at carbon(34).碳(34)位上藤黄酸衍生物的化学结构修饰和构效关系研究。
Chem Biodivers. 2012 Oct;9(10):2295-308. doi: 10.1002/cbdv.201200081.
9
Discovery of a Highly Potent and Novel Gambogic Acid Derivative as an Anticancer Drug Candidate.发现一种高效新型藤黄酸衍生物作为抗癌药物候选物。
Anticancer Agents Med Chem. 2021;21(9):1110-1119. doi: 10.2174/1871520620666200408080040.
10
Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay.通过高通量筛选试验发现、表征藤黄酸作为一种强效凋亡诱导剂及其构效关系。
Bioorg Med Chem. 2004 Jan 15;12(2):309-17. doi: 10.1016/j.bmc.2003.11.013.

引用本文的文献

1
Biomembrane-coated nanosystems as next-generation delivery systems for the treatment of gastrointestinal cancers.生物膜包被的纳米系统作为治疗胃肠道癌症的下一代递送系统。
Bioeng Transl Med. 2025 Feb 26;10(4):e70006. doi: 10.1002/btm2.70006. eCollection 2025 Jul.
2
Gambogic acid suppresses osteosarcoma progression through upregulation of FOXO3a.藤黄酸通过上调FOXO3a抑制骨肉瘤进展。
Discov Oncol. 2025 Jun 13;16(1):1083. doi: 10.1007/s12672-025-02776-w.
3
Isogarcinol Reduces MARS Levels and Deactivates the PI3K/AKT Pathway to Suppress the Malignant Properties of Breast Cancer Cells.

本文引用的文献

1
A multiple environment-sensitive prodrug nanomicelle strategy based on chitosan graftomer for enhanced tumor therapy of gambogic acid.基于壳聚糖接枝物的多环境敏感前药纳米胶束策略增强藤黄酸的肿瘤治疗。
Carbohydr Polym. 2021 Sep 1;267:118229. doi: 10.1016/j.carbpol.2021.118229. Epub 2021 May 20.
2
Gambogic Acid as a Candidate for Cancer Therapy: A Review.藤黄酸作为癌症治疗的候选药物:综述。
Int J Nanomedicine. 2020 Dec 22;15:10385-10399. doi: 10.2147/IJN.S277645. eCollection 2020.
3
Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer.
异藤黄醇降低MARS水平并使PI3K/AKT信号通路失活,从而抑制乳腺癌细胞的恶性特性。
Cell Biochem Biophys. 2025 Mar 22. doi: 10.1007/s12013-025-01727-0.
4
FeO nanoparticles containing gambogic acid inhibit metastasis in colorectal cancer via the RORB/EMILIN1 axis.载藤黄酸的 FeO 纳米颗粒通过 RORB/EMILIN1 轴抑制结直肠癌转移。
Cell Adh Migr. 2024 Dec;18(1):38-53. doi: 10.1080/19336918.2024.2427585. Epub 2024 Nov 13.
5
Gambogic acid: Multi-gram scale isolation, stereochemical erosion toward epi-gambogic acid and biological profile.藤黄酸:多克级规模的分离、向表藤黄酸的立体化学转变及生物学特性
Front Nat Prod. 2022;1. doi: 10.3389/fntpr.2022.1018765.
6
Nano-Drug Delivery Systems Based on Natural Products.基于天然产物的纳米药物传递系统。
Int J Nanomedicine. 2024 Jan 18;19:541-569. doi: 10.2147/IJN.S443692. eCollection 2024.
7
Natural Products Inhibition of Cytochrome P450 2B6 Activity and Methadone Metabolism.天然产物对细胞色素P450 2B6活性及美沙酮代谢的抑制作用
Drug Metab Dispos. 2024 Feb 14;52(3):252-265. doi: 10.1124/dmd.123.001578.
8
Gambogic acid affects high glucose-induced apoptosis and inflammation of retinal endothelial cells through the NOX4/NLRP3 pathway.藤黄酸通过NOX4/NLRP3途径影响高糖诱导的视网膜内皮细胞凋亡和炎症。
Ann Transl Med. 2023 Feb 28;11(4):168. doi: 10.21037/atm-22-6591. Epub 2023 Feb 16.
9
Polyphenols: Chemoprevention and therapeutic potentials in hematological malignancies.多酚类物质:血液系统恶性肿瘤中的化学预防及治疗潜力
Front Nutr. 2022 Oct 26;9:1008893. doi: 10.3389/fnut.2022.1008893. eCollection 2022.
藤黄酸增强吉西他滨在非小细胞肺癌中的抗癌活性。
Eur J Pharmacol. 2020 Dec 5;888:173486. doi: 10.1016/j.ejphar.2020.173486. Epub 2020 Aug 14.
4
Combined Omics Approach Identifies Gambogic Acid and Related Xanthones as Covalent Inhibitors of the Serine Palmitoyltransferase Complex.联合组学方法鉴定藤黄酸和相关紫檀芪为丝氨酸棕榈酰转移酶复合物的共价抑制剂。
Cell Chem Biol. 2020 May 21;27(5):586-597.e12. doi: 10.1016/j.chembiol.2020.03.008. Epub 2020 Apr 23.
5
Discovery of a Highly Potent and Novel Gambogic Acid Derivative as an Anticancer Drug Candidate.发现一种高效新型藤黄酸衍生物作为抗癌药物候选物。
Anticancer Agents Med Chem. 2021;21(9):1110-1119. doi: 10.2174/1871520620666200408080040.
6
Tumor Microenvironment Stimuli-Responsive Polymeric Prodrug Micelles for Improved Cancer Therapy.肿瘤微环境刺激响应型聚合物前药胶束用于改善癌症治疗。
Pharm Res. 2019 Dec 10;37(1):4. doi: 10.1007/s11095-019-2709-1.
7
Polymeric micelles loading with ursolic acid enhancing anti-tumor effect on hepatocellular carcinoma.负载熊果酸的聚合物胶束增强对肝细胞癌的抗肿瘤作用。
J Cancer. 2019 Oct 6;10(23):5820-5831. doi: 10.7150/jca.30865. eCollection 2019.
8
Gambogic acid suppresses colon cancer cell activity .藤黄酸抑制结肠癌细胞活性。
Exp Ther Med. 2019 Oct;18(4):2917-2923. doi: 10.3892/etm.2019.7912. Epub 2019 Aug 16.
9
Gambogic acid triggers vacuolization-associated cell death in cancer cells via disruption of thiol proteostasis.藤黄酸通过破坏巯基稳态来触发癌细胞中的空泡化相关细胞死亡。
Cell Death Dis. 2019 Feb 22;10(3):187. doi: 10.1038/s41419-019-1360-4.
10
Glutathione-sensitive PEGylated curcumin prodrug nanomicelles: Preparation, characterization, cellular uptake and bioavailability evaluation.谷胱甘肽敏感的聚乙二醇化姜黄素前药纳米胶束的制备、表征、细胞摄取和生物利用度评价。
Int J Pharm. 2019 Jan 30;555:270-279. doi: 10.1016/j.ijpharm.2018.11.049. Epub 2018 Nov 22.